The first US generic version of GlaxoSmithKline’s (GSK’s) Advair Diskus (fluticasone/salmeterol) will hit the market by the end of February with the launch of Mylan’s Wixela Inhub, the generics firm has revealed.
Approved by the US Food and Drug Administration (FDA) this week, Wixela Inhub gives Mylan around a year’s head-start on...




